Pregnenolone for the Treatment of Alcohol Use Disorder

Description

This Phase 2 randomized cotrolled trial (RCT) will assess the safety and efficacy of pregnenolone (PREG; 300 mg/day, b.i.d dosing) vs. placebo (PBO) over a 12 week treatment period, and at 1-month post-treatment follow-up in individuals with Alcohol Use Disorder (AUD).

Conditions

Alcohol Use Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

This Phase 2 randomized cotrolled trial (RCT) will assess the safety and efficacy of pregnenolone (PREG; 300 mg/day, b.i.d dosing) vs. placebo (PBO) over a 12 week treatment period, and at 1-month post-treatment follow-up in individuals with Alcohol Use Disorder (AUD).

Pregnenolone for the Treatment of Alcohol Use Disorder

Pregnenolone for the Treatment of Alcohol Use Disorder

Condition
Alcohol Use Disorder
Intervention / Treatment

-

Contacts and Locations

New Haven

The Yale Stress Center: Yale University, New Haven, Connecticut, United States, 06519

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male or female individuals, ages 18 to 70.
  • * Subjects must meet current Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) criteria for alcohol use disorder; documented positive urine toxicology screen for alcohol at intake or collateral information from family members, significant others, room-mates etc., on recent use.
  • * Subject has voluntarily given informed consent and signed the informed consent document.
  • * Able to read English and complete study evaluations.
  • * Women who are pregnant, or nursing or are of childbearing potential and not practicing an effective means of birth control.
  • * Meet current criteria for use disorder on another psychoactive substance, such as, heroin, amphetamines, hallucinogens/Phencyclidine (PCP), excluding alcohol and nicotine.
  • * Any current use of opiates or past history of opiate use disorder (assessed via urine toxicology and self report).
  • * Current use of any psychoactive drugs (urine toxicology), including anxiolytics, naltrexone or antabuse.
  • * Any psychotic disorder or current Axis I psychiatric symptoms requiring specific attention.
  • * Significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study.
  • * Hypotensive individuals with sitting blood pressure below 90/50 mmHG.

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Yale University,

Study Record Dates

2028-07-31